Skip to main navigation
  • Skip to main content
  • Skip to primary sidebar
Imara

Investor Relations

  • Who We Are
    • Management
    • Board of Directors
  • Investors
    • Press Releases
    • Events and Presentations
    • Stock Information
      • Analyst Coverage
    • SEC Filings
    • Corporate Governance
    • Investor FAQs
    • Contact IR
    • Email Alerts
  • Contact Us

Investors

Breadcrumb

Investors » Investor Relations

Investor Relations

Corporate Profile

Imara Inc. has been dedicated to developing and commercializing novel therapeutics to treat patients suffering from serious diseases.
Change
Volume
52 Week High
52 Week Low
Jan 27, 2023 4:59 PM EST

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Press Releases
Oct 13, 2022
Enliven Therapeutics and Imara Announce Merger Agreement
Apr 05, 2022
Imara Announces Results of Interim Analyses of Tovinontrine (IMR-687) Phase 2b Clinical Trials in Sickle Cell Disease and Beta-Thalassemia
Mar 15, 2022
Imara Reports Full Year 2021 Financial Results and Business Highlights
Events
Oct 13, 2022 at 5:00 PM EDT
Imara Inc Conference Call

Footer Social Link

Imara, Inc.
116 Huntington Ave.
6th Floor
Boston, MA 02116
T: 617-206-2020
E: info@imaratx.com

Privacy Policy
Terms of Use
© 2023 Imara, Inc.